Welcome to our dedicated page for Iridex news (Ticker: IRIX), a resource for investors and traders seeking the latest updates and insights on Iridex stock.
Iridex Corporation (IRIX) delivers innovative laser-based medical systems for ophthalmology, specializing in noninvasive treatments for glaucoma and retinal diseases. This news hub provides investors and healthcare professionals with timely updates on product developments, financial performance, and clinical advancements.
Access authoritative information about IRIX's proprietary MicroPulse technology, regulatory milestones, and global market initiatives. Our curated collection features earnings announcements, partnership updates, and clinical study results – all essential for tracking the company's position in medical device innovation.
Discover updates across key categories including new product clearances, international distribution expansions, and peer-reviewed research findings. Content is regularly updated to reflect IRIX's progress in enhancing ophthalmic care through advanced laser systems and procedural tools.
Bookmark this page for streamlined access to verified Iridex developments. Combine strategic business insights with technical expertise through our comprehensive news repository – your primary source for monitoring this medical technology leader's trajectory.
Iridex (NASDAQ:IRIX) has released preliminary Q1 2025 financial results, showing signs of business stabilization. The company expects total revenue between $11.8-12.0 million, comparable to Q1 2024's $11.8 million.
Key operational metrics include sales of approximately 13,900 Cyclo G6 probes (up from 13,300 year-over-year) and 24 Cyclo G6 Laser Systems (up from 22). Cash and cash equivalents stood at $7.2 million as of March 29, 2025.
The company reports improved financial condition following strategic investment from Novel Inspiration International Co., , with consecutive quarterly revenue increases while reducing operating expenses. Management indicates potential for breakeven or better performance at historical revenue levels, despite exposure to external factors like tariff policy changes.
Iridex (Nasdaq: IRIX), a leading provider of laser-based medical systems for glaucoma and retinal diseases, has announced a strategic vision call scheduled for April 16, 2025. The call will outline the company's strategic direction following Novel's recent strategic investment.
The conference call is set to begin at 2:00 p.m. PT / 5:00 p.m. ET. Investors can participate by dialing 888-596-4144 with conference ID: 9584140. Both a live and recorded webcast will be accessible through the 'Event Calendar' section on Iridex's investor relations website.
Iridex (IRIX) reported its Q4 and full year 2024 financial results, highlighting positive adjusted EBITDA in Q4 2024. The company generated Q4 revenue of $12.7 million, up from $12.5 million year-over-year, while implementing cost reductions that decreased operating expenses by 24% to $6.1 million.
Key Q4 metrics include Cyclo G6® product revenue of $3.3 million and Retina product revenue of $7.3 million. The company's net loss improved to $0.8 million from $3.0 million in the prior year quarter. For full year 2024, total revenue was $48.7 million, down from $51.9 million in 2023.
Notably, Iridex secured a strategic investment of $10 million at $2.00 per share, with an option for an additional $10 million for future growth. The company expects to achieve cash flow breakeven and positive adjusted EBITDA in 2025 on revenue consistent with 2024 levels.
Iridex (NASDAQ: IRIX) has secured a strategic investment of $10 million from Novel Inspiration International Co., , with an option for an additional $10 million for future growth initiatives. The initial transaction includes $6 million in new Series B Preferred Stock and $4 million in convertible notes, both priced at $2.00 per share equivalent.
The convertible notes have a three-year term with 12% interest, payable quarterly in common stock. Novel has the right to appoint two board members, with William Moore, former CEO and board member, joining the board. The funding will be used to repay existing debt and for general corporate purposes.
The company also announced the appointment of Romeo Dizon as CFO, replacing Interim CFO Fuad Ahmad. This strategic investment aims to enhance Iridex's ability to pursue opportunities in advanced laser-based treatments, particularly following the November 2024 LCD that introduced new limitations for MIGS devices.
Iridex (NASDAQ: IRIX), a provider of laser-based medical systems for glaucoma and retinal diseases treatment, has addressed recent stock price volatility observed on March 13, 2025. The company explicitly stated there are no material developments or changes to its operating or financial condition that would explain the recent price and volume movements.
The company confirmed that no material adverse changes have occurred to its operating results, business, strategy, or prospects since their preliminary Q4 and full year 2024 results announcement on January 14, 2025. Final financial results will be discussed during a conference call scheduled for March 27, 2025, at 2:00pm PT.
Iridex (NASDAQ: IRIX), a provider of laser-based medical systems for glaucoma and retinal diseases treatment, has scheduled its Fourth Quarter and Full Year 2024 financial results announcement for March 27, 2025, after market close.
The company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET on the same day. Investors can join via phone at +1-888-596-4144 (Conference ID: 5685253) or access the webcast through the Event Calendar on Iridex's investor relations website.
Iridex (IRIX) has released preliminary Q4 and full-year 2024 results. Q4 revenue is expected between $12.6-12.7 million, slightly up from $12.5 million in Q4 2023. The company maintained stable Cyclo G6® probe sales at 12,700 units and increased Cyclo G6 Glaucoma Laser Systems sales to 47 units from 35 year-over-year.
Full-year 2024 revenue is projected at $48.6-48.7 million, down from $51.9 million in 2023. Annual Cyclo G6® probe sales decreased to 54,800 from 55,200, while Glaucoma Laser Systems sales declined to 125 from 164 units. The company reports progress in cost restructuring initiatives and achieving positive EBITDA in Q4 2024. A strategic review process with multiple parties remains ongoing.
Iridex (IRIX) announced a landmark five-year peer-reviewed study published in Ophthalmology Therapy, demonstrating the long-term effectiveness of their MicroPulse Transscleral Laser Therapy (TLT) for glaucoma treatment. The study, conducted at University Eye Clinic Maastricht, evaluated 165 eyes with 112 completing the five-year follow-up.
Key findings showed significant results using the Cyclo G6® Laser and MicroPulse P3® Delivery Device: a 32.5% average reduction in intraocular pressure (IOP), decreased need for IOP-lowering medications, and only 38% of eyes requiring retreatment. The study confirms TLT as a viable alternative to invasive surgery, with sustained effectiveness and minimal complications across various glaucoma types.
Iridex (Nasdaq: IRIX) confirms the adoption of Local Coverage Determination (LCD) L37531 for Micro-Invasive Glaucoma Surgery (MIGS), effective November 17, 2024. The new LCD clarifies that Iridex's laser-based treatments are not MIGS procedures and remain unaffected by new reimbursement limitations. The company's Cyclo G6® product family, which currently sells over 50,000 probes annually, offers noninvasive, repeatable treatments across various stages of glaucoma progression. The LCD's restrictions on MIGS procedures are expected to increase physician interest in Iridex's laser-based alternatives.
Iridex reported its third quarter 2024 financial results, showing a total revenue of $11.6 million, a sequential decline of 8% from Q2 2024 and a 10% decline from Q3 2023. The Cyclo G6 product family generated $3.1 million in revenue, a 3% increase from Q3 2023. However, retina product revenue fell to $6.5 million, a 12% sequential decline and an 18% drop year-over-year. The company strengthened its balance sheet with $3.4 million in net proceeds from a convertible note offering. Cash and cash equivalents were approximately $3.9 million as of September 28, 2024.
Iridex expects to achieve EBITDA breakeven in Q4 2024 due to cost-cutting measures. The company also announced new Local Coverage Determinations (LCDs) for Medicare reimbursement, effective November 17, 2024, which could boost the use of its glaucoma products. The company is undergoing a strategic review and is in discussions with multiple parties regarding potential transactions.
